Q2/2025 6/30/2025 EPS -0.330 ZacksConsensus -0.350 ActVsEst 0.020 - Beat
Longeveron Inc. - common stock (LGVN)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
LGVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGVN alerts
High impacting Longeveron Inc. - common stock news events
Weekly update
A roundup of the hottest topics
LGVN
News
- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]Yahoo! Finance
- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem CellGlobeNewswire
- Longeveron appoints new CEO [Seeking Alpha]Seeking Alpha
- Longeveron® Appoints Stephen H. Willard as Chief Executive OfficerGlobeNewswire
- Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher ProgramGlobeNewswire
LGVN
Earnings
- 11/4/25 - Miss
LGVN
Sec Filings
- 3/3/26 - Form PRE
- 2/13/26 - Form 8-K
- 2/10/26 - Form SCHEDULE
- LGVN's page on the SEC website